BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10524687)

  • 1. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial.
    Felson DT; LaValley MP; Baldassare AR; Block JA; Caldwell JR; Cannon GW; Deal C; Evans S; Fleischmann R; Gendreau RM; Harris ER; Matteson EL; Roth SH; Schumacher HR; Weisman MH; Furst DE
    Arthritis Rheum; 1999 Oct; 42(10):2153-9. PubMed ID: 10524687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis.
    Gendreau RM;
    Ther Apher; 2001 Apr; 5(2):79-83. PubMed ID: 11354303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Prosorba column apheresis in patients with chronic refractory rheumatoid arthritis.
    Roth S
    J Rheumatol; 2004 Nov; 31(11):2131-5. PubMed ID: 15517623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis.
    Caldwell J; Gendreau RM; Furst D; Wiesenhutter C; Quagliata F; Spindler J; Bertram J
    J Rheumatol; 1999 Aug; 26(8):1657-62. PubMed ID: 10451058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ; Wells G; Verhoeven AC; Felson DT
    Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators.
    Furst D; Felson D; Thoren G; Gendreau RM
    Ther Apher; 2000 Oct; 4(5):363-73. PubMed ID: 11111818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
    Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
    Sanmartí R; Marsal S; Valverde J; Casado E; Lafuente R; Kashiwagi N; Rodriguez-Cros JR; Erra A; Reina D; Gratacós J
    Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.
    Yocum DE; Furst DE; Kaine JL; Baldassare AR; Stevenson JT; Borton MA; Mengle-Gaw LJ; Schwartz BD; Wisemandle W; Mekki QA;
    Arthritis Rheum; 2003 Dec; 48(12):3328-37. PubMed ID: 14673984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.